A Proliferative Subtype of Colorectal Liver Metastases Exhibits Hypersensitivity to Cytotoxic Chemotherapy

Overview

Journal NPJ Precis Oncol

Publisher Springer Nature

Specialty Oncology

Date 2022 Oct 14

PMID 36241710

Authors

Liam F Spurr

Carlos A Martinez

Rohan R Katipally

Soumya C Iyer

Sian A Pugh

John A Bridgewater

John N Primrose

Enric Domingo

Timothy S Maughan

Michael I DAngelica

Mark Talamonti

Mitchell C Posner

Philip P Connell

Ralph R Weichselbaum

Sean P Pitroda

Affiliations

Soon will be listed here.

Abstract

Personalized treatment approaches for patients with limited liver metastases from colorectal cancer are critically needed. By leveraging three large, independent cohorts of patients with colorectal liver metastases (n = 336), we found that a proliferative subtype associated with elevated CIN70 scores is linked to immune exclusion, increased metastatic proclivity, and inferior overall survival in colorectal liver metastases; however, high CIN70 scores generate a therapeutic vulnerability to DNA-damaging therapies leading to improved treatment responses. We propose CIN70 as a candidate biomarker to personalize systemic treatment options for patients with metastatic colorectal cancer. These findings are potentially broadly applicable to other human cancers.

Citing Articles

Cell Migration-Proliferation Dichotomy in Cancer: Biological Fact or Experimental Artefact?.

Alfahed A Biology (Basel). 2024; 13(10).

PMID: 39452063 PMC: 11504154. DOI: 10.3390/biology13100753.

TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.

Boland P, Mukherjee S, Imanirad I, Vijayvergia N, Cohen S, Gupta M Br J Cancer. 2024; 131(8):1290-1297.

PMID: 39244627 PMC: 11473817. DOI: 10.1038/s41416-024-02845-x.

SBRT for Liver Tumors: What the Interventional Radiologist Needs to Know.

Gutman M, Serra L, Koshy M, Katipally R Semin Intervent Radiol. 2024; 41(1):1-10.

PMID: 38495259 PMC: 10940045. DOI: 10.1055/s-0043-1778657.

Transcriptomic Maps of Colorectal Liver Metastasis: Machine Learning of Gene Activation Patterns and Epigenetic Trajectories in Support of Precision Medicine.

Ashekyan O, Shahbazyan N, Bareghamyan Y, Kudryavzeva A, Mandel D, Schmidt M Cancers (Basel). 2023; 15(15).

PMID: 37568651 PMC: 10417131. DOI: 10.3390/cancers15153835.

References

Pitroda S, Khodarev N, Huang L, Uppal A, Wightman S, Ganai S . Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018; 9(1):1793. PMC: 5935683. DOI: 10.1038/s41467-018-04278-6. View

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(12):1208-15. DOI: 10.1016/S1470-2045(13)70447-9. View

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371(9617):1007-16. PMC: 2277487. DOI: 10.1016/S0140-6736(08)60455-9. View

Chen T, Sun Y, Ji P, Kopetz S, Zhang W . Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene. 2014; 34(31):4019-31. PMC: 4404185. DOI: 10.1038/onc.2014.332. View

Kanas G, Taylor A, Primrose J, Langeberg W, Kelsh M, Mowat F . Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012; 4:283-301. PMC: 3496330. DOI: 10.2147/CLEP.S34285. View

Balachandran V, Arora A, Gonen M, Ito H, Turcotte S, Shia J . A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. Clin Cancer Res. 2016; 22(10):2575-82. PMC: 4978939. DOI: 10.1158/1078-0432.CCR-15-1071. View

Yard B, Adams D, Chie E, Tamayo P, Battaglia J, Gopal P . A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun. 2016; 7:11428. PMC: 4848553. DOI: 10.1038/ncomms11428. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Carter S, Eklund A, Kohane I, Harris L, Szallasi Z . A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006; 38(9):1043-8. DOI: 10.1038/ng1861. View

10.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

11.

Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View

12.

Bestvina C, Pointer K, Karrison T, Al-Hallaq H, Hoffman P, Jelinek M . A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2021; 17(1):130-140. DOI: 10.1016/j.jtho.2021.08.019. View

13.

Kanemitsu Y, Shimizu Y, Mizusawa J, Inaba Y, Hamaguchi T, Shida D . Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial. J Clin Oncol. 2021; 39(34):3789-3799. DOI: 10.1200/JCO.21.01032. View

14.

Swanton C, Nicke B, Schuett M, Eklund A, Ng C, Li Q . Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A. 2009; 106(21):8671-6. PMC: 2688979. DOI: 10.1073/pnas.0811835106. View

15.

Hveem T, Merok M, Pretorius M, Novelli M, Baevre M, Sjo O . Prognostic impact of genomic instability in colorectal cancer. Br J Cancer. 2014; 110(8):2159-64. PMC: 3992498. DOI: 10.1038/bjc.2014.133. View

16.

Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T . Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018; 173(4):879-893.e13. PMC: 6132060. DOI: 10.1016/j.cell.2018.03.041. View

17.

Domingo E, Camps C, Kaisaki P, Parsons M, Mouradov D, Pentony M . Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. Lancet Gastroenterol Hepatol. 2018; 3(9):635-643. PMC: 6088509. DOI: 10.1016/S2468-1253(18)30117-1. View

18.

Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012; 29(1):15-21. PMC: 3530905. DOI: 10.1093/bioinformatics/bts635. View

19.

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N . The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25(16):2078-9. PMC: 2723002. DOI: 10.1093/bioinformatics/btp352. View

20.

Mouradov D, Domingo E, Gibbs P, Jorissen R, Li S, Soo P . Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol. 2013; 108(11):1785-93. DOI: 10.1038/ajg.2013.292. View